Insiders · PRLD

PRLD insider transactions

Prelude Therapeutics Incorporated (PRLD) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for PRLD

• 34d
  SEC Form 4 filed by Chief Medical Officer Morris Charles Q

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 40d
  Large owner Ra Capital Management, L.P. disposed of 1,407,000 shares (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 40d
  New insider Ra Capital Management, L.P. claimed ownership of 7,882,882 shares (SEC Form 3)

  3 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 45d
  Director Bonita David P bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 45d
  Director Orbimed Advisors Llc bought $12,499,999 worth of shares (2,815,315 units at $4.44) (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 46d
  SEC Form 4 filed by Baker Bros. Advisors Lp

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 53d
  SEC Form 3 filed by new insider Morris Charles Q

  3 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 80d
  SEC Form 3 filed by new insider Brusky Sean P.

  3 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 122d
  SEC Form 4 filed by Chief Chemistry Officer Combs Andrew

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 122d
  SEC Form 4 filed by Chief Scientific Officer Scherle Peggy

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 122d
  SEC Form 4 filed by CLO, CFO, Corp Sec. Lim Bryant David

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 122d
  SEC Form 4 filed by CEO Vaddi Krishna

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 212d
  SEC Form 4 filed by Director Sandor Victor

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 230d
  SEC Form 3 filed by new insider Dorton Katina

  3 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 244d
  President, CMO Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,355 shares, increasing direct ownership by 7% to 86,917 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 334d
  President, CMO Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,355 shares, increasing direct ownership by 8% to 80,897 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 359d
  SEC Form 4 filed by Director Baker Bros. Advisors Lp

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 359d
  SEC Form 3 filed by new insider Scherer Paul C

  3 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 359d
  SEC Form 4 filed by Director Sandor Victor

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 359d
  SEC Form 4 filed by Director Dier Mardi

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 359d
  SEC Form 4 filed by Director Friedman Paul A

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 359d
  SEC Form 4 filed by Director Bonita David P

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 359d
  SEC Form 4 filed by Director Babler Martin

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 426d
  President, CMO Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,355 shares, increasing direct ownership by 9% to 74,877 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 437d
  Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 437d
  CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 440d
  CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 446d
  CEO Vaddi Krishna bought $29,460 worth of shares (39,105 units at $0.75), increasing direct ownership by 3% to 1,303,880 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 450d
  CEO Vaddi Krishna bought $69,564 worth of shares (97,500 units at $0.71), increasing direct ownership by 8% to 1,264,775 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 487d
  SEC Form 4 filed by CLO, CFO, Corp Sec. Lim Bryant David

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 487d
  SEC Form 4 filed by Chief Scientific Officer Scherle Peggy

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 487d
  SEC Form 4 filed by Chief Chemistry Officer Combs Andrew

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 487d
  SEC Form 4 filed by President, CMO Huang Jane

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 487d
  SEC Form 4 filed by CEO Vaddi Krishna

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 516d
  President, CMO Huang Jane covered exercise/tax liability with 3,859 shares and converted options into 9,375 shares, increasing direct ownership by 9% to 68,857 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 520d
  CEO Vaddi Krishna bought $6,044 worth of shares (5,000 units at $1.21) (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 521d
  CEO Vaddi Krishna bought $12,000 worth of shares (10,000 units at $1.20) (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 528d
  Chief Chemistry Officer Combs Andrew bought $85,538 worth of shares (63,075 units at $1.36), increasing direct ownership by 20% to 377,623 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 534d
  CLO, Interim CFO, Corp Sec. Lim Bryant David bought $22,638 worth of shares (25,000 units at $0.91), increasing direct ownership by 1,042% to 27,400 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 534d
  CEO Vaddi Krishna bought $99,326 worth of shares (106,888 units at $0.93), increasing direct ownership by 9% to 1,167,275 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 699d
  President, CMO Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,347 shares, increasing direct ownership by 12% to 57,315 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 719d
  SEC Form 4 filed by Director Baker Bros. Advisors Lp

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 719d
  SEC Form 4 filed by Director Sandor Victor

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 719d
  SEC Form 4 filed by Director Friedman Paul A

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 719d
  SEC Form 4 filed by Director Dier Mardi

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 719d
  SEC Form 4 filed by Director Bonita David P

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 719d
  SEC Form 4 filed by Director Babler Martin

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 752d
  SEC Form 4 filed by Lim Bryant David

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 790d
  Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,347 shares, increasing direct ownership by 13% to 51,287 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 825d
  SEC Form 4 filed by Lim Bryant David

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 825d
  SEC Form 4 filed by Scherle Peggy

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 825d
  SEC Form 4 filed by Combs Andrew

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 825d
  SEC Form 4 filed by Chardonnet Laurent

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 825d
  SEC Form 4 filed by Huang Jane

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 825d
  SEC Form 4 filed by Vaddi Krishna

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 881d
  Huang Jane converted options into 9,375 shares and covered exercise/tax liability with 3,844 shares, increasing direct ownership by 14% to 45,259 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 907d
  SEC Form 4 filed by Baker Bros. Advisors Lp

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 975d
  Huang Jane converted options into 9,375 shares, increasing direct ownership by 31% to 39,728 units (SEC Form 4)

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 1067d
  SEC Form 4 filed by Huang Jane

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)
• 1082d
  SEC Form 4 filed by Baker Bros. Advisors Lp

  4 - Prelude Therapeutics Inc (0001678660) (Issuer)